David Lebovitz
Stock Analyst at Citigroup
(2.97)
# 1,170
Out of 4,667 analysts
91
Total ratings
62.86%
Success rate
4.77%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $56.07 | +31.98% | 2 | Nov 14, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $93 → $81 | $62.56 | +29.48% | 2 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $382 → $371 | $317.09 | +17.00% | 3 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $291 → $342 | $248.79 | +37.47% | 30 | Aug 2, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $43.69 | -13.02% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $41.96 | -59.49% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $94.81 | -2.96% | 6 | Feb 1, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $59.36 | -9.03% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $35.40 | -1.13% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $3.28 | +418.29% | 11 | Apr 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $3.52 | +212.50% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $124.38 | +59.99% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $34 → $32 | $0.78 | +4,029.03% | 2 | Nov 3, 2020 |
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $56.07
Upside: +31.98%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Neutral
Price Target: $93 → $81
Current: $62.56
Upside: +29.48%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Buy
Price Target: $382 → $371
Current: $317.09
Upside: +17.00%
Alnylam Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $291 → $342
Current: $248.79
Upside: +37.47%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $43.69
Upside: -13.02%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $41.96
Upside: -59.49%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $94.81
Upside: -2.96%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $59.36
Upside: -9.03%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $35.40
Upside: -1.13%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $3.28
Upside: +418.29%
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $3.52
Upside: +212.50%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $124.38
Upside: +59.99%
Nov 3, 2020
Maintains: Overweight
Price Target: $34 → $32
Current: $0.78
Upside: +4,029.03%